Abstract
Target therapy is licensed by United States Food and Drug Administration on certain cancers. Both sorafenib and lenvatinib are tyrosine kinase inhibitor and indicated on radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Lenvatinib is more effective in cancers' control than sorafenib, but causes more nephrotoxicity than sorafenib does. This case is the second published case about the serial adaptions from lenvatinib to sorafenib for improving the proteinuria and, meanwhile, achieving the therapeutic goal. A 56-year-old man suffered from bilateral edematous lower extremities after 1-mo prescription of lenvatinib of 20 mg/d for RAI-refractory DTC. Aside from this symptom, he also developed hypertension. His laboratory showed grade-3 proteinuria (estimated 24-h urine protein: 9993 mg), hypoalbuminemia and hypercholesterolemia. Anti-vascular endothelial growth factor (VEGF) therapy-induced nephrotic syndrome was impressed. After reduced dosage of lenvatinib of 10 mg/d and related symptomatic drugs, limited improvement was observed in both adverse effects and caner control. Under this condition, we substituted sorafenib of 400 mg/d for lenvatinib of 10 mg/d. After a 5-mo prescription, not only hypertension and ...Continue Reading
References
Jan 17, 2003·Stem Cells·David S Goodsell
Apr 20, 2004·Current Opinion in Nephrology and Hypertension·Vera Eremina, Susan E Quaggin
Oct 17, 2009·The American Journal of Pathology·Samy HakroushWilhelm Kriz
Nov 1, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Rawi RamadanZaid Abassi
Sep 27, 2013·Kidney International·Hassan IzzedineDjillali Sahali
Apr 29, 2014·Lancet·Marcia S BroseUNKNOWN DECISION investigators
Feb 12, 2015·The New England Journal of Medicine·Martin SchlumbergerSteven I Sherman
Oct 21, 2015·The Lancet Oncology·Robert J MotzerJames Larkin
Feb 13, 2016·Nature Reviews. Endocrinology·Cristina RomeiRossella Elisei
Feb 13, 2018·Lancet·Masatoshi KudoAnn-Lii Cheng
Apr 14, 2018·Critical Reviews in Oncology/hematology·Yuchen JinLibo Chen
May 22, 2018·Auris, Nasus, Larynx·Hideaki GotoHironobu Minami
Dec 7, 2018·Case Reports in Oncology·Yasuko HyogoHironobu Minami
Dec 24, 2018·European Thyroid Journal·Luisa PaschkeRalf Paschke
Aug 1, 2019·British Journal of Cancer·Thomas R Jeffry EvansMax W Sung
Nov 27, 2019·European Thyroid Journal·Laura FugazzolaJan Smit
Apr 30, 2020·International Journal of Clinical Oncology·Chie MasakiKoichi Ito